Efficacy and safety of caspofungin in obese patients

Medical Mycology

Volumn 49, Issue 7, 2011, Pages 748-754

  Ryan, Desmond M ^a   Lupinacci, Robert J ^a   Kartsonis, Nicholas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

aspergillosis; candidiasis; caspofungin; empirical therapy; obesity

Indexed keywords

CASPOFUNGIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEVER; HEADACHE; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; NAUSEA; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM BLOOD LEVEL; RETROSPECTIVE STUDY; SIDE EFFECT; SYSTEMIC MYCOSIS;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; ECHINOCANDINS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80052591450     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.571293     Document Type: Article

References (20)

1. Pappas PG, Kauffman, CA, Andes D, et al . Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 : 503-535.
2. Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: the fi rst in a new class of antifungal agents. Drug Resist Update 2003; 6 : 197-218. (Pubitemid 37129919)
3. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49 : 4536-4545. (Pubitemid 41552583)
4. Villanueva A, Arathoon EG, Gotuzzo E, et al . A randomized doubleblind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33 : 1533-1535
5. Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, doubleblind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46 : 451-457. (Pubitemid 34087195)
6. DiNubile MJ, Lupinacci RJ, Berman R, Sable CA. Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res Human Retrovir 2002; 18 : 903-908.
7. Villanueva A, Gotuzzo E, Arathoon EG, et al . A randomized doubleblind study of caspofungin versus fl uconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113 : 294-299. (Pubitemid 35287295)
8. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347 : 2020-2029. (Pubitemid 35461658)
9. Cornely OA, Lasso M, Betts R, et al . Caspofungin for treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60 : 363-369. (Pubitemid 47243887)
10. Betts RF, Nucci M, Talwar D, et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48 : 1676-1684.
11. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39 : 1563-1571. (Pubitemid 39578526)
12. Walsh TJ, Teppler H, Donowitz GR, et al . Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351 : 1391-1402.
13. Ascioglu S, Rex JH, de Pauw B, et al. Defi ning opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34 : 7-14. (Pubitemid 33152659)
14. Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48 : 815-823. (Pubitemid 38280330)
15. Stone JA, Holland SD, Wickersham PJ, et al. Single- and multipledose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46 : 739-745. (Pubitemid 34157659)
16. Nguyen TH, Hoppe-Tichy T, Geiss HK, et al . Factors infl uencing caspofungin plasma concentration in patients of a surgical intensive care unit. J Antimicrob Chemother 2007; 60 : 100-106. (Pubitemid 47073282)
17. Gumbo T, Hiemenz J, Ma L, Keirns JJ, et al . Population pharmacokinetics of micafungin in adult patients. Diag Micrbiol Infect 2008; 60 : 329-331. (Pubitemid 351253603)
18. Dowell JA, Knebal W, Ludden T, et al . Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44 : 590-598. (Pubitemid 38668021)
19. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 2006; 354 : 1667-1669.
20. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine reporting of subgroup analyses in clinical trials. N Engl J Med 2007; 357 : 2189-2194.